Dec'04 | Dec'05 | Dec'06 | Dec'07 | Dec'08 | Dec'09 | Dec'10 | Dec'11 | Dec'12 | Dec'13 | Dec'14 | Dec'15 | Dec'16 | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue | $36.6B | $39.4B | $42.8B | $45.5B | $45.1B | $44.4B | $43.9B | $43.9B | $41.9B | $41.5B | $37.9B | $36.6B | $37.8B | $38.9B | $41.1B | $43.1B | $43.8B | $46.9B | $36.3B | $37.7B |
Discover the top 20 best undervalued stocks to buy for Dec 2024, listed on the Nasdaq or NYSE.
Discover the top 20 best undervalued large-cap growth stocks to buy for Dec 2024, listed on the Nasdaq or NYSE.
Discover the top 20 best undervalued high-yield dividend stock that offers both growth potential and attractive dividend returns for Dec 2024.
As of today, GSK plc's last 12-month Revenue is $39.8B, based on the financial report for Sep 30, 2024 (Q3 2024).
Over the last year, GSK plc's Revenue growth was 9.4%. The average annual Revenue growth rates for GSK plc have been (2.1%) over the past three years, (1.2%) over the past five years.
Over the last year, GSK plc's Revenue growth was 9.4%, which is higher than industry growth of 0.1%. It indicates that GSK plc's Revenue growth is Good.